Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D

PHASE1RecruitingINTERVENTIONAL

Enrollment

134

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

December 20, 2025

Study Completion Date

February 20, 2026

Conditions

Diabetes

Interventions

DRUG

RZ-629

Administered orally

DRUG

Placebo

Administered orally

OTHER

Fasted

Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout

OTHER

Fed

Participants will be treated with RZ-629 in fasted or fed condition and then cross over after washout

Trial Locations (1)

RECRUITING

CMAX, Adelaide

All Listed Sponsors

lead

Rezubio Pharmaceuticals Co., Ltd.

INDUSTRY